Figure 3.

FENO may act through PPARα and AMPK phosphorylation. Treatment of obese, metabolically inflexible HSkMC with FENO in combination with GW6471, Compound C, or AICAR as indicated, show that FENO-induced increases in FAO are inhibited by co-incubation with PPARα antagonist or AMPK inhibitor, though FENO treatment with AMPK activation by AICAR does not increase FAO beyond that of FENO alone (A). Similar observations are made for phosphorylated AMPK/Total AMPK protein levels (Thr172) (B). Data are mean ± SEM. * indicates significant difference from 24hFA condition.